- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Seth Ginsberg: Biologics and Prior Authorization
Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, discusses the impact of prior authorization requirements on patients and providers.
Transcript:
How do prior authorizations affect patients who have been prescribed biologics?
Like “fail first,” prior authorization is a tactic used by health insurance providers to reduce prescription drug costs. They serve an important purpose in seeking to reduce healthcare costs; however, when they are excessive in length and difficult to navigate because of variance, and depending on the insurance company requirements, prior authorization can become a real barrier to care.
By requiring physicians to submit additional paperwork to prove that a patient requires an advanced therapy—sometimes still requiring the use of a fax machine—they are encouraging physicians to prescribe an older, possibly less effective option to avoid the prior authorization effort required by the insurer. Physicians often report having to dedicate several staff members full time to processing prior authorization forms for patients. And from the patient perspective, prior authorization requirements mean that accessing their prescription is delayed, which can lead to serious health consequences or complications, not to mention much more stress.
Legislative efforts to address this issue have focused on streamlining and bringing uniformity to prior authorization forms and appeals processes within states around the country.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
